First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Authors: Wermke Martin , Holderried Tobias A W , Luke Jason John , Morris Van K , Alsdorf Winfried H , Wetzko Katrin , Andersson Borje S , Wistuba Ignacio I , Parra Edwin R , Hossain Mohammad B , Grund-Gröschke Sandra , Aslan Katrin , Satelli Arun , Marisetty Anantha , Satam Swapna , Kalra Mamta , Hukelmann Jens , Kursunel M Alper , Pozo Karine , Acs Andreas , Backert Linus , Baumeister Melissa , Bunk Sebastian , Wagner Claudia , Schoor Oliver , Mohamed Ali S , Mayer-Mokler Andrea , Hilf Norbert , Krishna Delfi , Walter Steffen , Tsimberidou Apostolia M , Britten Cedrik M 
Published: July 2024

Rationale of the trial

Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.

Trial design

The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8+T cells expressing a T cell receptor (TCR), which is specific for a nine amino acid peptide derived from MAGEA1. Eligible patients underwent leukapheresis, T cells were isolated, transduced with lentiviral vector carrying MAGEA1-specific TCR and following lymphodepletion (fludarabine/cyclophosphamide), infused with a median of 1.4×109specific T cells (range, 0.086×109–2.57×109) followed by interleukin 2.

Safety of IMA202

No DLT was observed. The most common grade 3–4 adverse events were cytopenias, that is, neutropenia (81.3%), lymphopenia (75.0%), anemia (50.0%), thrombocytopenia (50.0%) and leukopenia (25.0%). 13 patients experienced cytokine release syndrome, including one grade 3 event. Immune effector cell-associated neurotoxicity syndrome was observed in two patients and was grade 1 in both.

Efficacy of IMA202

Of the 16 patients dosed, 11 (68.8%) patients had stable disease (SD) as their best overall response (Response Evaluation Criteria in Solid Tumors V.1.1). Five patients had initial tumor shrinkage in target lesions and one patient with SD experienced continued shrinkage in target lesions for 3 months in total but had to be classified as progressive disease due to progressive non-target lesions. IMA202 T cells were persistent in peripheral blood for several weeks to months and were also detectable in tumor tissue. Peak persistence was higher in patients who received higher doses.

Conclusion

In conclusion, IMA202 had a manageable safety profile, and it was associated with biological and potential clinical activity of MAGEA1-targeting genetically engineered TCR-T cells in a poor prognosis, multi-indication solid tumor cohort.

Trial registration numbers

NCT04639245,NCT05430555.